



Belgian Cancer Registry

CANCER FACT SHEET 2023

CANCER OF THE BILIARY SYSTEM

ICD-10 C22-C24



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2023, obtained from the Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE	5
1.1. Cancer of the biliary system incidence: by region	5
1.1.1. Cancer of the biliary system incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023.....	5
1.2. Cancer of the biliary system incidence: by tumour type	7
1.2.1. Cancer of the biliary system incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	7
1.3. Cancer of the biliary system incidence: by tumour location and tumour type and tumour stage	7
1.3.1. Cancer of the biliary system incidence by location, type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	7
2. CANCER INCIDENCE TRENDS	9
2.1. Cancer of the biliary system incidence trends: by region	9
2.1.1. Cancer of the biliary system incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	9
2.1.2. Cancer of the biliary system incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	11
2.2. Cancer of the biliary system incidence trends: by tumour type.....	12
2.2.1. Cancer of the biliary system incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards... ..	12
2.3. Cancer of the biliary system incidence trends: by tumour location and tumour type and tumour stage	13
2.3.1. Cancer of the biliary system incidence trends by location, type, stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards.....	13
2.4. Cancer of the biliary system incidence trends: by age group.....	18
2.4.1. Cancer of the biliary system incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	18
2.4.2. Cancer of the biliary system incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	19
3. CANCER PREVALENCE	20
3.1. Cancer of the biliary system prevalence: by region.....	20
3.1.1. Cancer of the biliary system prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023	20
4. CANCER SURVIVAL.....	21
4.1. Cancer of the biliary system survival: by region	21
4.1.1. Cancer of the biliary system survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023	21
4.2. Cancer of the biliary system survival: by tumour type	23
4.2.1. Cancer of the biliary system survival by type and sex: number at risk and net survival probabilities, 2014-2023	23
4.3. Cancer of the biliary system survival: by tumour location and tumour type and tumour stage	24

4.3.1. Cancer of the biliary system survival by location, type, stage and sex: number at risk and net survival probabilities, 2014-2023	24
5. CANCER SURVIVAL TRENDS.....	27
5.1. Cancer of the biliary system survival trends: by tumour type.....	27
5.1.1. Cancer of the biliary system survival trends by type and sex: number at risk and net survival probabilities, 2004-2023.....	27
5.2. Cancer of the biliary system survival trends: by tumour location and tumour type and tumour stage.....	29
5.2.1. Cancer of the biliary system survival trends by location, type, stage and sex: number at risk and net survival probabilities, 2004-2023.....	29
6. CANCER MORTALITY	34
6.1. Cancer of the biliary system mortality: by region	34
6.1.1. Cancer of the biliary system mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	34
7. CANCER MORTALITY TRENDS.....	36
7.1. Cancer of the biliary system mortality trends: by region	36
7.1.1. Cancer of the biliary system mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	36
7.1.2. Cancer of the biliary system mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	37

1. CANCER INCIDENCE



1.1. Cancer of the biliary system incidence: by region

1.1.1. *Cancer of the biliary system incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023*

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	2	0	0	3	1	4	4	4	6	27	28	83	155	202	223	192	105	82	20	0	1,141	20.9
	[0.7]	[0.0]	[0.0]	[0.9]	[0.3]	[1.1]	[1.0]	[1.1]	[1.6]	[7.2]	[7.1]	[20.6]	[41.4]	[63.5]	[83.7]	[94.4]	[84.1]	[102.9]	[63.8]	[0.0]	[19.8]	(19.6; 22.1)
Brussels	0	0	0	1	1	1	1	1	1	7	5	9	20	10	13	11	8	8	1	0	98	23.8
	[0.0]	[0.0]	[0.0]	[2.7]	[2.5]	[2.0]	[1.9]	[2.1]	[2.2]	[15.9]	[12.2]	[25.4]	[69.4]	[46.8]	[77.3]	[87.1]	[99.5]	[159.9]	[43.4]	[0.0]	[16.1]	(18.9; 28.6)
Flanders	0	0	0	0	0	2	1	2	4	12	13	45	82	109	114	117	60	51	15	0	627	18.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[0.5]	[0.9]	[1.8]	[5.7]	[5.7]	[18.6]	[35.8]	[55.6]	[69.5]	[89.8]	[72.8]	[94.8]	[72.1]	[0.0]	[18.7]	(16.9; 19.8)
Wallonia	2	0	0	2	0	1	2	1	1	8	10	29	53	83	96	64	37	23	4	0	416	24.9
	[2.1]	[0.0]	[0.0]	[1.8]	[0.0]	[0.9]	[1.7]	[0.9]	[0.9]	[6.8]	[8.0]	[23.2]	[45.3]	[82.3]	[112.4]	[106.1]	[107.6]	[109.9]	[48.6]	[0.0]	[23.1]	(22.5; 27.3)
Females																						
Belgium	0	1	0	0	2	1	2	6	2	14	27	28	51	81	100	92	78	77	22	0	584	9.0
	[0.0]	[0.3]	[0.0]	[0.0]	[0.6]	[0.3]	[0.5]	[1.6]	[0.5]	[3.8]	[7.0]	[7.1]	[13.4]	[23.9]	[33.7]	[37.4]	[44.8]	[57.5]	[31.0]	[0.0]	[9.8]	(8.3; 9.7)
Brussels	0	0	0	0	0	0	0	0	0	0	3	4	4	9	9	11	5	4	3	0	52	10.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[7.8]	[11.7]	[13.2]	[36.0]	[42.0]	[61.1]	[38.9]	[40.8]	[52.9]	[0.0]	[8.2]	(7.7; 13.6)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	0	0	2	0	2	5	2	7	14	14	29	41	49	53	53	49	14	0	334	8.4
	[0.0]	[0.0]	[0.0]	[0.0]	[1.1]	[0.0]	[0.9]	[2.3]	[0.9]	[3.4]	[6.2]	[5.9]	[12.7]	[20.3]	[27.9]	[35.3]	[48.4]	[57.4]	[31.8]	[0.0]	[9.8]	(7.5; 9.3)
Wallonia	0	1	0	0	0	1	0	1	0	7	10	10	18	31	42	28	20	24	5	0	198	9.7
	[0.0]	[1.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.8]	[0.0]	[5.9]	[8.0]	[7.9]	[14.6]	[27.8]	[42.0]	[36.2]	[38.5]	[62.1]	[23.6]	[0.0]	[10.5]	(8.3; 11.0)

1.2. Cancer of the biliary system incidence: by tumour type

1.2.1. Cancer of the biliary system incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

type	Males					Females				
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
Cholangiocarcinoma	45 [1.3]	132 [13.8]	117 [26.3]	294 [5.1]	5.4 (4.8; 6.0)	34 [1.0]	89 [8.7]	122 [18.9]	245 [4.1]	3.7 (3.3; 4.2)
Hepatocellular carcinoma	90 [2.7]	361 [37.6]	196 [44.0]	648 [11.2]	11.8 (10.8; 12.7)	18 [0.5]	79 [7.8]	68 [10.5]	166 [2.8]	2.6 (2.2; 3.0)
Adenocarcinoma	17 [0.5]	68 [7.1]	55 [12.4]	140 [2.4]	2.6 (2.2; 3.0)	18 [0.5]	61 [6.0]	51 [7.9]	130 [2.2]	2.0 (1.7; 2.4)
Other and unspecified	8 [0.2]	19 [2.0]	31 [7.0]	59 [1.0]	1.1 (0.8; 1.4)	12 [0.4]	3 [0.3]	28 [4.3]	43 [0.7]	0.6 (0.4; 0.8)

1.3. Cancer of the biliary system incidence: by tumour location and tumour type and tumour stage

1.3.1. Cancer of the biliary system incidence by location, type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

type	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
Hepatic Cholangiocarcinoma	I	3 [0.1]	15 [1.6]	10 [2.2]	28 [0.5]	0.5 (0.3; 0.7)	1 [0.0]	8 [0.8]	11 [1.7]	20 [0.3]	0.3 (0.2; 0.4)
	II	6 [0.2]	14 [1.5]	9 [2.0]	29 [0.5]	0.5 (0.3; 0.7)	5 [0.2]	6 [0.6]	7 [1.1]	18 [0.3]	0.3 (0.2; 0.4)
	III	2 [0.1]	13 [1.4]	11 [2.5]	26 [0.5]	0.5 (0.3; 0.7)	3 [0.1]	6 [0.6]	15 [2.3]	24 [0.4]	0.4 (0.2; 0.5)

type	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
	IV	20 [0.6]	53 [5.5]	37 [8.3]	110 [1.9]	2.0 (1.6; 2.4)	17 [0.5]	39 [3.8]	38 [5.9]	94 [1.6]	1.5 (1.2; 1.7)
	X/NA	1 [0.0]	3 [0.3]	6 [1.3]	10 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	3 [0.3]	7 [1.1]	11 [0.2]	0.2 (0.1; 0.3)
Cholangiocarcinoma of gallbladder & biliary tract	X/NA	13 [0.4]	34 [3.5]	44 [9.9]	91 [1.6]	1.7 (1.3; 2.0)	7 [0.2]	27 [2.7]	44 [6.8]	78 [1.3]	1.2 (0.9; 1.4)
Hepatocellular carcinoma	I	23 [0.7]	105 [10.9]	48 [10.8]	176 [3.1]	3.2 (2.7; 3.7)	4 [0.1]	26 [2.6]	18 [2.8]	48 [0.8]	0.8 (0.5; 1.0)
	II	28 [0.8]	104 [10.8]	49 [11.0]	181 [3.1]	3.3 (2.8; 3.7)	4 [0.1]	16 [1.6]	11 [1.7]	32 [0.5]	0.5 (0.3; 0.7)
	III	15 [0.4]	59 [6.2]	48 [10.8]	122 [2.1]	2.2 (1.8; 2.6)	3 [0.1]	14 [1.4]	16 [2.5]	33 [0.6]	0.5 (0.3; 0.7)
	IV	15 [0.4]	67 [7.0]	35 [7.9]	117 [2.0]	2.1 (1.7; 2.5)	5 [0.2]	20 [2.0]	16 [2.5]	41 [0.7]	0.7 (0.5; 0.9)
	X/NA	9 [0.3]	26 [2.7]	16 [3.6]	52 [0.9]	0.9 (0.7; 1.2)	2 [0.1]	3 [0.3]	7 [1.1]	12 [0.2]	0.2 (0.1; 0.3)
Adenocarcinoma of gallbladder & biliary tract	I	0 [0.0]	11 [1.1]	11 [2.5]	22 [0.4]	0.4 (0.2; 0.6)	1 [0.0]	6 [0.6]	9 [1.4]	16 [0.3]	0.2 (0.1; 0.3)
	II	2 [0.1]	11 [1.1]	7 [1.6]	20 [0.3]	0.4 (0.2; 0.5)	4 [0.1]	9 [0.9]	14 [2.2]	27 [0.5]	0.4 (0.3; 0.6)
	III	10 [0.3]	15 [1.6]	12 [2.7]	37 [0.6]	0.7 (0.5; 0.9)	5 [0.2]	18 [1.8]	13 [2.0]	36 [0.6]	0.6 (0.4; 0.7)
	IV	2 [0.1]	11 [1.1]	8 [1.8]	21 [0.4]	0.4 (0.2; 0.6)	5 [0.2]	22 [2.2]	8 [1.2]	35 [0.6]	0.6 (0.4; 0.7)
	X/NA	2 [0.1]	8 [0.8]	11 [2.5]	21 [0.4]	0.4 (0.2; 0.6)	3 [0.1]	4 [0.4]	6 [0.9]	13 [0.2]	0.2 (0.1; 0.3)
Other and unspecified	I	0 [0.0]	3 [0.3]	3 [0.7]	6 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	II	1 [0.0]	2 [0.2]	3 [0.7]	6 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	2 [0.2]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)
	III	0 [0.0]	3 [0.3]	4 [0.9]	7 [0.1]	0.1 (0.0; 0.3)	1 [0.0]	0 [0.0]	3 [0.5]	4 [0.1]	0.1 (0.0; 0.1)
	IV	3 [0.1]	15 [1.6]	14 [3.1]	32 [0.6]	0.6 (0.4; 0.8)	3 [0.1]	2 [0.2]	11 [1.7]	16 [0.3]	0.2 (0.1; 0.3)
	X/NA	5 [0.1]	8 [0.8]	13 [2.9]	27 [0.5]	0.5 (0.3; 0.7)	7 [0.2]	1 [0.1]	13 [2.0]	21 [0.4]	0.3 (0.2; 0.4)

2. CANCER INCIDENCE TRENDS



2.1. Cancer of the biliary system incidence trends: by region

2.1.1. *Cancer of the biliary system incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023*

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium N	413	437	501	541	600	581	685	741	791	802	804	890	938	961	966	1,089	1,000	1,044	1,125	1,141		
CR	8.1	8.5	9.7	10.4	11.5	11.0	12.9	13.8	14.6	14.7	14.7	16.2	16.9	17.3	17.3	19.3	17.7	18.4	19.7	19.8		
ESR2013	10.0	10.4	11.9	12.6	13.8	12.9	15.4	16.1	16.9	17.0	16.7	18.5	19.1	19.3	19.0	21.2	19.1	19.9	21.0	20.9	4.0 (3.5; 4.4)	2004-2023
																					6.9 (5.6; 8.2)	2004-2011
																					3.4 (1.5; 5.3)	2012-2015
																					1.7 (0.7; 2.7)	2016-2023
Brussels N	27	40	49	47	49	62	78	66	89	72	74	74	78	97	76	87	84	81	102	98		
CR	5.6	8.3	10.0	9.5	9.7	12.0	14.8	12.2	16.1	12.8	13.1	12.9	13.5	16.7	13.0	14.7	14.1	13.5	17.0	16.1		
ESR2013	8.2	11.5	14.9	13.9	14.7	17.2	21.6	18.7	24.2	20.0	20.6	20.0	21.2	26.8	19.5	22.8	22.3	20.6	26.3	23.8	4.6 (3.6; 5.6)	2004-2023
																					11.6 (8.3; 15.0)	2004-2011
																					0.8 (-0.9; 2.4)	2012-2023
Flanders N	234	249	272	285	332	319	364	388	403	418	390	455	496	480	513	565	531	540	599	627		
CR	7.9	8.4	9.1	9.4	10.9	10.4	11.8	12.5	12.9	13.3	12.3	14.3	15.5	14.9	15.8	17.3	16.2	16.4	18.1	18.7		
ESR2013	9.2	9.7	10.7	11.0	12.6	11.6	13.3	13.7	14.0	14.4	13.1	15.3	16.4	15.6	16.3	17.8	16.3	16.6	17.9	18.4	3.6 (3.2; 4.0)	2004-2023
																					6.0 (4.5; 7.6)	2004-2010

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
																					2.5 (1.9; 3.1)	2011-2023
Wallonia N	152	148	180	209	219	200	243	287	299	312	340	361	364	384	377	437	385	423	424	416		
CR	9.3	9.0	10.9	12.5	13.1	11.8	14.3	16.7	17.3	18.0	19.5	20.6	20.7	21.8	21.3	24.6	21.6	23.7	23.7	23.1		
ESR2013	11.8	11.4	13.5	15.3	16.1	14.4	17.8	20.2	21.1	21.2	23.2	24.7	23.7	24.9	24.5	27.7	24.1	26.2	26.0	24.9	4.4 (3.9; 4.9)	2004-2023
																					7.6 (6.6; 8.7)	2004-2014
																					1.0 (-0.1; 2.1)	2015-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Cancer of the biliary system incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium N	294	326	322	334	388	418	422	440	431	457	486	469	490	475	566	491	547	574	566	584		
CR	5.5	6.1	6.0	6.2	7.1	7.6	7.6	7.9	7.7	8.1	8.6	8.2	8.6	8.3	9.8	8.5	9.4	9.8	9.6	9.8		
ESR2013	5.5	6.1	6.0	6.1	7.1	7.5	7.5	7.7	7.4	7.9	8.2	7.9	8.2	7.8	9.3	8.1	8.6	9.2	8.8	9.0	2.6 (2.1; 3.0)	2004-2023
																					5.2 (3.5; 7.0)	2004-2010
																					1.1 (-0.9; 3.2)	2011-2014
																					1.5 (0.5; 2.5)	2015-2023
Brussels N	25	38	36	26	32	44	51	49	45	39	57	43	56	50	49	42	47	58	51	52		
CR	4.8	7.3	6.8	4.9	5.9	8.0	9.1	8.5	7.7	6.6	9.6	7.1	9.2	8.2	8.0	6.8	7.6	9.3	8.2	8.2		
ESR2013	5.0	7.6	7.5	5.7	6.8	9.5	10.7	10.0	9.0	8.1	12.2	8.7	11.6	10.2	9.3	8.7	9.3	11.8	10.4	10.6	2.7 (1.4; 4.0)	2004-2023
																					5.5 (2.7; 8.4)	2004-2014
																					-0.4 (-3.4; 2.8)	2015-2023
Flanders N	188	197	199	203	228	244	211	244	245	239	284	265	270	263	325	267	315	318	326	334		
CR	6.2	6.4	6.5	6.5	7.3	7.8	6.7	7.6	7.6	7.4	8.8	8.1	8.2	8.0	9.8	8.0	9.4	9.5	9.6	9.8		
ESR2013	6.2	6.4	6.3	6.3	7.1	7.3	6.3	7.2	7.1	6.9	8.1	7.4	7.5	7.2	8.9	7.2	8.2	8.3	8.3	8.4	1.6 (1.1; 2.1)	2004-2023
Wallonia N	81	91	87	105	128	130	160	147	141	179	145	161	164	162	192	182	185	198	189	198		
CR	4.7	5.2	5.0	5.9	7.2	7.3	8.9	8.1	7.7	9.8	7.9	8.7	8.9	8.8	10.4	9.8	9.9	10.6	10.1	10.5		
ESR2013	4.6	5.3	5.1	5.9	7.2	7.4	8.8	8.2	7.6	9.7	7.5	8.5	8.7	8.3	9.8	9.5	9.3	10.1	9.4	9.7	4.3 (3.6; 4.9)	2004-2023
																					11.7 (8.6; 14.8)	2004-2009
																					1.7 (0.9; 2.6)	2010-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Cancer of the biliary system incidence trends: by tumour type

2.2.1. Cancer of the biliary system incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

type		Males							Females						
		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Cholangiocarcinoma	N	209	244	230	270	294			144	188	168	198	245		
	CR	3.7	4.3	4.1	4.7	5.1			2.5	3.2	2.9	3.4	4.1		
	ESR2013	4.0	4.6	4.4	5.0	5.4	5.2 (4.2; 6.3)	2004-2023	2.4	3.1	2.7	3.1	3.7	4.9 (4.1; 5.8)	2004-2023
Hepatocellular carcinoma	N	624	550	573	665	648			155	157	167	166	166		
	CR	11.1	9.7	10.1	11.6	11.2			2.7	2.7	2.9	2.8	2.8		
	ESR2013	12.1	10.5	10.8	12.3	11.8	4.6 (4.1; 5.1)	2004-2023	2.5	2.5	2.7	2.6	2.6	3.3 (2.6; 4.1)	2004-2023
							8.7 (7.4; 9.9)	2004-2013						7.8 (5.7; 10.0)	2004-2012
							1.2 (0.2; 2.2)	2014-2023						0.2 (-1.2; 1.6)	2013-2023
Adenocarcinoma	N	161	143	157	123	140			128	135	158	122	130		
	CR	2.9	2.5	2.8	2.2	2.4			2.2	2.3	2.7	2.1	2.2		
	ESR2013	3.2	2.8	3.0	2.3	2.6	0.3 (-0.6; 1.2)	2004-2023	2.1	2.1	2.5	1.9	2.0	-0.7 (-1.5; 0.1)	2004-2023
Other and unspecified	N	95	63	84	67	59			64	67	81	80	43		
	CR	1.7	1.1	1.5	1.2	1.0			1.1	1.1	1.4	1.4	0.7		
	ESR2013	1.9	1.2	1.7	1.3	1.1	3.6 (1.5; 5.8)	2004-2023	1.0	1.0	1.2	1.2	0.6	2.3 (0.8; 3.8)	2004-2023
														5.8 (2.3; 9.5)	2004-2013
														-0.8 (-3.7; 2.2)	2014-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Cancer of the biliary system incidence trends: by tumour location and tumour type and tumour stage

2.3.1. Cancer of the biliary system incidence trends by location, type, stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Stage		Males							Females															
		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period									
Hepatic Cholangiocarcinoma																								
I	N	19	11	22	16	28			9	15	15	16	20											
	CR	0.3	0.2	0.4	0.3	0.5			0.2	0.3	0.3	0.3	0.3											
	ESR2013	0.4	0.2	0.4	0.3	0.5			12.3 (8.0; 16.7)	2004-2023	0.2	0.3	0.3			0.3	0.3	13.4 (9.0; 18.1)	2004-2023					
II	N	17	24	27	23	29			14	18	10	15	18											
	CR	0.3	0.4	0.5	0.4	0.5			0.2	0.3	0.2	0.3	0.3											
	ESR2013	0.3	0.5	0.5	0.4	0.5			13.1 (9.2; 17.2)	2004-2023	0.2	0.3	0.2			0.2	0.3	12.3 (8.7; 16.1)	2004-2023	20.9 (11.8; 30.8)	2004-2013	5.1 (-1.9; 12.7)	2014-2023	
III	N	24	19	20	20	26			15	13	15	17	24											
	CR	0.4	0.3	0.4	0.4	0.5			0.3	0.2	0.3	0.3	0.4											
	ESR2013	0.5	0.4	0.4	0.4	0.5			7.0 (-0.7; 15.4)	2004-2023	0.3	0.2	0.2			0.2	0.4	0.0 (-5.8; 6.2)	2004-2023	-13.4 (-24.8; -0.3)	2004-2015	43.2 (16.9; 75.4)	2016-2023	-19.6 (-29.9; -7.7)
IV	N	59	107	78	102	110			61	81	69	79	94											
	CR	1.0	1.9	1.4	1.8	1.9			1.1	1.4	1.2	1.3	1.6											
	ESR2013	1.1	2.0	1.5	1.9	2.0			14.1 (12.6; 15.6)	2004-2023	1.0	1.4	1.1			1.3	1.5	13.9 (12.2; 15.6)	2004-2023	23.4 (19.2; 27.8)	2004-2012	7.8 (5.2; 10.4)	2013-2023	8.0 (5.4; 10.7)

Stage		Males							Females								
		2019	2020	2021	2022	2023	AAPC, % (95%CI)		Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)		Period
X/NA	N	10	14	3	13	10				9	6	7	5	11			
	CR	0.2	0.2	0.1	0.2	0.2				0.2	0.1	0.1	0.1	0.2			
	ESR2013	0.2	0.3	0.1	0.2	0.2	-6.4 (-9.6; -3.1)		2004-2023	0.2	0.1	0.1	0.1	0.2	-5.6 (-8.1; -3.1)		2004-2023
							1.3 (-5.7; 8.9)		2004-2014						4.6 (-0.4; 9.9)		2004-2015
							-14.3 (-21.0; -7.1)		2015-2023						-18.1 (-23.7; -12.0)		2016-2023
Cholangiocarcinoma of gallblader & biliary tract																	
X/NA	N	80	68	80	96	91				37	55	52	66	78			
	CR	1.4	1.2	1.4	1.7	1.6				0.6	0.9	0.9	1.1	1.3			
	ESR2013	1.6	1.3	1.5	1.8	1.7	9.6 (6.2; 13.2)		2004-2023	0.6	0.9	0.8	1.1	1.2	6.5 (4.3; 8.8)		2004-2023
							16.3 (8.6; 24.7)		2004-2013								
							-5.3 (-18.1; 9.5)		2014-2017								
						10.6 (-1.5; 24.2)		2018-2023									
Hepatocellular carcinoma																	
I	N	147	132	142	169	176				29	48	45	53	48			
	CR	2.6	2.3	2.5	3.0	3.1				0.5	0.8	0.8	0.9	0.8			
	ESR2013	2.8	2.5	2.7	3.1	3.2	11.9 (11.0; 12.9)		2004-2023	0.5	0.8	0.8	0.9	0.8	9.1 (7.3; 11.0)		2004-2023
							17.2 (14.2; 20.2)		2004-2011						17.4 (10.5; 24.7)		2004-2010
							9.0 (7.5; 10.5)		2012-2023						5.5 (2.9; 8.2)		2011-2023
II	N	117	126	113	143	181				26	31	30	39	32			
	CR	2.1	2.2	2.0	2.5	3.1				0.4	0.5	0.5	0.7	0.5			
	ESR2013	2.3	2.4	2.1	2.6	3.3	7.5 (5.5; 9.6)		2004-2023	0.4	0.5	0.5	0.6	0.5	6.3 (4.1; 8.6)		2004-2023
															21.4 (8.4; 36.0)		2004-2008
														2.6 (0.1; 5.2)		2009-2023	
III	N	114	109	135	127	122				33	25	47	29	33			

Stage		Males							Females												
		2019	2020	2021	2022	2023	AAPC, % (95%CI)		Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)		Period				
IV	CR	2.0	1.9	2.4	2.2	2.1				0.6	0.4	0.8	0.5	0.6							
	ESR2013	2.2	2.1	2.6	2.4	2.2	5.2 (4.1; 6.4)		2004-2023	0.5	0.4	0.8	0.5	0.5	4.2 (0.8; 7.7)		2004-2023				
	N	105	100	120	151	117				31	25	26	26	41							
	CR	1.9	1.8	2.1	2.6	2.0				0.5	0.4	0.4	0.4	0.7							
	ESR2013	2.0	2.0	2.3	2.8	2.1	10.0 (8.5; 11.6)		2004-2023	0.5	0.4	0.4	0.4	0.7	7.7 (4.4; 11.1)		2004-2023				
							19.6 (13.6; 25.8)		2004-2010												
							5.9 (3.7; 8.2)		2011-2023												
X/NA	N	141	83	63	75	52				36	28	19	19	12							
	CR	2.5	1.5	1.1	1.3	0.9				0.6	0.5	0.3	0.3	0.2							
	ESR2013	2.7	1.6	1.2	1.4	0.9	-4.6 (-5.7; -3.4)		2004-2023	0.6	0.4	0.3	0.3	0.2	-5.4 (-6.2; -4.5)		2004-2023				
							6.9 (4.6; 9.3)		2004-2015						6.2 (4.4; 7.9)		2004-2015				
							-18.4 (-20.9; -15.8)		2016-2023						-19.2 (-21.1; -17.3)		2016-2023				
	Adenocarcinoma of gallblader & biliary tract																				
	I	N	22	19	11	19	22				11	12	19	20	16						
		CR	0.4	0.3	0.2	0.3	0.4				0.2	0.2	0.3	0.3	0.3						
ESR2013		0.4	0.4	0.2	0.4	0.4	-2.5 (-4.3; -0.7)		2004-2023	0.2	0.2	0.3	0.3	0.2	-4.5 (-6.9; -2.1)		2004-2023				
							-6.8 (-10.4; -3.1)		2004-2014						-10.3 (-14.5; -6.0)		2004-2015				
II							2.5 (-1.9; 7.1)		2015-2023						4.1 (-2.7; 11.3)		2016-2023				
	N	14	19	15	14	20				13	14	20	23	27							
	CR	0.2	0.3	0.3	0.2	0.3				0.2	0.2	0.3	0.4	0.5							
	ESR2013	0.3	0.4	0.3	0.3	0.4	-4.5 (-6.6; -2.4)		2004-2023	0.2	0.2	0.3	0.3	0.4	-3.6 (-5.5; -1.7)		2004-2023				
III	N	28	23	23	29	37				22	26	28	25	36							
	CR	0.5	0.4	0.4	0.5	0.6				0.4	0.4	0.5	0.4	0.6							
	ESR2013	0.5	0.4	0.4	0.5	0.7	9.7 (6.6; 13.0)		2004-2023	0.3	0.4	0.5	0.4	0.6	8.1 (5.0; 11.1)		2004-2023				

Stage		Males							Females								
		2019	2020	2021	2022	2023	AAPC, % (95%CI)		Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)		Period
IV	N	23	21	25	15	21				25	26	43	27	35			
	CR	0.4	0.4	0.4	0.3	0.4				0.4	0.4	0.7	0.5	0.6			
	ESR2013	0.5	0.4	0.5	0.3	0.4	1.5 (-0.3; 3.3)		2004-2023	0.4	0.4	0.7	0.4	0.6	2.0 (-0.1; 4.0)		2004-2023
X/NA	N	59	48	60	31	21				45	44	37	16	13			
	CR	1.0	0.8	1.1	0.5	0.4				0.8	0.8	0.6	0.3	0.2			
	ESR2013	1.2	0.9	1.2	0.6	0.4	-2.7 (-4.8; -0.5)		2004-2023	0.7	0.6	0.6	0.2	0.2	-3.8 (-5.8; -1.8)		2004-2023
							3.1 (0.2; 6.1)		2004-2018						4.5 (1.0; 8.2)		2004-2016
								-17.2 (-24.6; -9.1)	2019-2023							-16.6 (-21.8; -11.1)	2017-2023
Other and unspecified																	
I	N	9	7	9	7	6				4	5	5	6	1			
	CR	0.2	0.1	0.2	0.1	0.1				0.1	0.1	0.1	0.1	0.0			
	ESR2013	0.2	0.1	0.2	0.1	0.1	7.2 (2.8; 11.7)		2004-2023	0.1	0.1	0.1	0.1	0.0	1.9 (-2.5; 6.6)		2004-2023
II	N	10	5	9	7	6				7	6	8	7	4			
	CR	0.2	0.1	0.2	0.1	0.1				0.1	0.1	0.1	0.1	0.1			
	ESR2013	0.2	0.1	0.2	0.1	0.1	3.9 (-0.2; 8.2)		2004-2023	0.1	0.1	0.1	0.1	0.1	0.8 (-2.4; 4.2)		2004-2023
							-7.8 (-16.6; 2.0)		2004-2011								
															6.2 (0.6; 12.1)	2012-2023	
III	N	17	11	14	10	7				9	6	14	10	4			
	CR	0.3	0.2	0.2	0.2	0.1				0.2	0.1	0.2	0.2	0.1			
	ESR2013	0.3	0.2	0.3	0.2	0.1	4.4 (0.1; 8.9)		2004-2023	0.2	0.1	0.2	0.1	0.1	0.4 (-4.2; 5.2)		2004-2023
							-3.2 (-11.4; 5.7)		2004-2014						-18.2 (-31.0; -3.0)		2004-2010
								13.6 (2.8; 25.6)	2015-2023					6.0 (-14.3; 31.1)		2011-2014	
														12.4 (1.6; 24.4)		2015-2023	
IV	N	25	20	33	25	32				16	28	28	35	16			

Stage		Males							Females						
		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
	CR	0.4	0.4	0.6	0.4	0.6	8.0 (4.6; 11.5)	2004-2023	0.3	0.5	0.5	0.6	0.3	5.3 (2.7; 8.0)	2004-2023
	ESR2013	0.5	0.4	0.6	0.5	0.6			0.2	0.4	0.4	0.5	0.2		
X/NA	N	49	33	42	33	27	1.1 (-0.8; 3.1)	2004-2023	39	35	37	33	21	0.0 (-1.5; 1.4)	2004-2023
	CR	0.9	0.6	0.7	0.6	0.5			0.7	0.6	0.6	0.6	0.4		
	ESR2013	1.0	0.6	0.8	0.7	0.5			0.6	0.5	0.5	0.5	0.3		
							8.7 (4.8; 12.7)	2004-2015						5.3 (2.1; 8.6)	2004-2014
							-8.4 (-13.0; -3.5)	2016-2023						-5.7 (-8.9; -2.3)	2015-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Cancer of the biliary system incidence trends: by age group

2.4.1. Cancer of the biliary system incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-59 N	104	107	114	131	128	143	159	160	183	161	151	166	182	176	174	168	164	124	175	160		
CR	3.3	3.3	3.5	4.0	3.9	4.4	4.8	4.8	5.5	4.8	4.5	5.0	5.5	5.3	5.2	5.0	4.9	3.7	5.2	4.7		
ESR2013	3.5	3.5	3.7	4.2	4.1	4.5	5.0	5.0	5.6	4.9	4.5	4.9	5.4	5.2	5.1	4.9	4.8	3.6	5.1	4.7	1.5 (0.7; 2.2)	2004-2023
																					5.6 (3.6; 7.6)	2004-2012
																					-1.4 (-2.7; -0.1)	2013-2023
60-74 N	182	207	243	262	303	274	318	362	350	407	391	470	476	488	494	551	501	549	546	580		
CR	26.7	30.2	35.4	37.4	42.5	37.7	42.9	47.9	45.5	52.0	49.1	57.8	57.2	57.0	56.2	61.3	54.6	58.7	57.7	60.5		
ESR2013	26.6	30.1	35.3	37.5	43.2	38.1	44.2	48.6	46.2	53.4	49.9	59.9	58.9	58.3	57.2	62.5	55.5	59.9	58.9	61.6	4.0 (3.5; 4.6)	2004-2023
																					7.2 (5.9; 8.5)	2004-2013
																					1.3 (0.2; 2.4)	2014-2023
75+ N	126	123	144	148	165	162	206	216	257	232	260	252	276	295	294	366	332	368	403	399		
CR	43.0	40.6	45.9	45.4	49.0	46.9	58.2	59.8	69.6	61.7	67.8	64.4	69.9	74.7	74.0	90.6	80.3	88.4	93.5	89.6		
ESR2013	39.2	37.3	43.5	44.2	46.6	44.1	57.2	57.2	66.7	58.4	64.8	63.2	68.7	73.3	72.3	88.6	79.3	87.5	91.8	88.1	4.8 (4.3; 5.4)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4.2. Cancer of the biliary system incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-59 N	55	59	44	56	63	74	70	74	89	77	74	70	71	76	94	73	90	81	67	82		
CR	1.8	1.9	1.4	1.8	2.0	2.3	2.2	2.3	2.7	2.3	2.3	2.1	2.2	2.3	2.9	2.2	2.7	2.5	2.0	2.5		
ESR2013	1.8	1.9	1.4	1.8	2.0	2.3	2.2	2.3	2.7	2.3	2.2	2.1	2.1	2.3	2.8	2.2	2.7	2.4	2.0	2.5	2.1 (1.0; 3.1)	2004-2023
																					6.3 (1.6; 11.2)	2004-2009
																					0.6 (-0.8; 2.0)	2010-2023
60-74 N	107	129	132	132	143	154	154	162	144	166	184	187	198	180	216	205	182	238	213	232		
CR	13.8	16.6	17.1	16.9	18.1	19.3	19.0	19.7	17.3	19.6	21.4	21.4	22.2	19.6	23.0	21.4	18.6	23.9	21.2	22.8		
ESR2013	13.3	16.3	16.8	16.6	18.2	19.5	19.3	19.9	17.6	19.9	21.9	21.9	22.7	19.8	23.3	21.5	18.8	24.0	21.4	23.0	2.5 (1.7; 3.3)	2004-2023
																					7.2 (2.6; 12.1)	2004-2008
																					1.6 (-1.8; 5.2)	2009-2012
																					1.2 (-0.1; 2.4)	2013-2023
75+ N	131	136	144	145	181	189	198	202	195	213	225	211	220	216	251	210	270	252	285	269		
CR	25.2	25.6	26.4	26.0	31.8	32.7	33.7	34.0	32.5	35.2	36.9	34.2	35.7	35.3	41.1	34.2	43.5	40.7	45.0	41.7		
ESR2013	25.2	25.3	26.0	25.6	32.3	32.3	33.2	34.1	31.7	35.7	36.3	33.5	35.3	35.0	41.2	35.1	43.4	41.4	45.2	41.4	3.2 (2.5; 3.9)	2004-2023
																					5.6 (3.2; 8.1)	2004-2010
																					0.6 (-2.3; 3.6)	2011-2014
																					2.8 (1.3; 4.2)	2015-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Cancer of the biliary system prevalence: by region

3.1.1. *Cancer of the biliary system prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023*

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	N	794	2,073	2,754	3,079	3,250	391	1,039	1,415	1,614	1,735
	CR	13.7	35.8	47.5	53	56	6.6	17.4	23.7	27	29
	ESR2013	14.2	37.1	49.4	55.3	58.5	6.0	16.1	21.9	24.9	26.7
Brussels	N	71	184	248	278	294	39	97	135	151	162
	CR	11.6	30.1	40.5	45.4	48.0	6.1	15.2	21.2	23.7	25.4
	ESR2013	16.7	45.0	61.4	68.8	73.0	8.1	19.6	27.2	30.5	32.7
Flanders	N	436	1,119	1,482	1,651	1,751	214	568	787	895	974
	CR	12.9	33.1	43.9	48.9	51.8	6.2	16.5	22.8	26.0	28.3
	ESR2013	12.5	32.2	42.7	47.6	50.6	5.4	14.5	20.1	22.8	24.7
Wallonia	N	287	770	1,024	1,150	1,205	138	374	493	568	599
	CR	15.9	42.6	56.7	63.6	66.7	7.3	19.8	26.2	30.1	31.8
	ESR2013	16.6	44.9	59.9	67.5	70.9	6.7	18.3	24.1	27.8	29.3

4. CANCER SURVIVAL



4.1. Cancer of the biliary system survival: by region

4.1.1. *Cancer of the biliary system survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023*

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	15,062	52.0% (51.2%; 52.9%)	30.3% (29.5%; 31.1%)	22.5% (21.7%; 23.4%)	16.2% (14.9%; 17.7%)
Males						
Belgium	All ages	9,875	53.2% (52.2%; 54.2%)	31.3% (30.2%; 32.3%)	23.2% (22.2%; 24.3%)	15.6% (14.1%; 17.3%)
	15-59	1,620	60.4% (58.1%; 62.9%)	39.1% (36.7%; 41.6%)	31.1% (28.7%; 33.7%)	24.0% (21.0%; 27.5%)
	60-74	5,020	56.0% (54.6%; 57.4%)	34.0% (32.6%; 35.5%)	26.0% (24.6%; 27.5%)	17.8% (15.9%; 19.9%)
	75+	3,235	45.2% (43.4%; 47.1%)	23.0% (21.3%; 24.9%)	14.8% (13.0%; 16.9%)	7.2% (4.6%; 11.4%)
Brussels	All ages	840	57.7% (54.3%; 61.2%)	34.4% (31.0%; 38.2%)	23.4% (20.0%; 27.4%)	14.0% (9.8%; 19.9%)
	15-59	205	63.4% (57.1%; 70.4%)	38.5% (32.0%; 46.2%)	30.3% (23.9%; 38.5%)	17.7% (10.0%; 31.3%)
	60-74	385	60.5% (55.7%; 65.8%)	38.3% (33.4%; 43.9%)	27.2% (22.4%; 33.1%)	20.0% (14.6%; 27.4%)
	75+	250	48.6% (42.4%; 55.7%)	25.3% (19.6%; 32.7%)	11.8% (7.0%; 20.1%)	FU<10y
Flanders	All ages	5,157	53.4% (52.0%; 54.8%)	32.1% (30.6%; 33.6%)	24.2% (22.7%; 25.8%)	17.6% (15.4%; 20.1%)
	15-59	758	62.1% (58.8%; 65.7%)	40.4% (37.0%; 44.2%)	33.2% (29.8%; 37.1%)	27.0% (23.0%; 31.6%)
	60-74	2,516	56.6% (54.6%; 58.6%)	35.5% (33.5%; 37.6%)	27.5% (25.5%; 29.7%)	20.7% (18.0%; 23.9%)
	75+	1,883	45.7% (43.3%; 48.1%)	24.1% (21.8%; 26.6%)	15.9% (13.5%; 18.7%)	9.2% (5.6%; 15.1%)
Wallonia	All ages	3,879	51.9% (50.3%; 53.5%)	29.5% (28.0%; 31.1%)	21.9% (20.3%; 23.6%)	13.6% (11.5%; 16.1%)

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	15-59	657	57.5% (53.9%; 61.5%)	37.7% (34.0%; 41.7%)	28.8% (25.3%; 32.9%)	22.1% (17.5%; 28.0%)
	60-74	2,120	54.4% (52.3%; 56.6%)	31.5% (29.4%; 33.7%)	24.0% (21.9%; 26.2%)	14.0% (11.4%; 17.3%)
	75+	1,102	43.7% (40.7%; 47.0%)	20.8% (18.1%; 23.9%)	13.7% (10.8%; 17.4%)	6.2% (2.9%; 13.1%)
Females						
Belgium	All ages	5,187	49.9% (48.5%; 51.3%)	28.5% (27.2%; 29.9%)	21.2% (19.9%; 22.7%)	17.3% (15.0%; 19.8%)
	15-59	769	66.5% (63.2%; 70.0%)	42.8% (39.4%; 46.6%)	31.7% (28.3%; 35.5%)	27.8% (24.2%; 31.9%)
	60-74	2,021	57.0% (54.8%; 59.2%)	32.7% (30.6%; 34.9%)	25.0% (23.0%; 27.3%)	19.3% (16.9%; 22.1%)
	75+	2,397	38.5% (36.5%; 40.6%)	20.3% (18.5%; 22.3%)	14.7% (12.8%; 16.9%)	12.4% (8.3%; 18.5%)
Brussels	All ages	493	52.0% (47.6%; 56.8%)	29.3% (25.2%; 34.1%)	23.8% (19.7%; 28.7%)	15.0% (10.5%; 21.5%)
	15-59	83	69.0% (59.6%; 79.9%)	40.7% (31.1%; 53.1%)	25.2% (16.6%; 38.3%)	20.0% (11.6%; 34.3%)
	60-74	185	59.9% (53.2%; 67.5%)	38.5% (31.7%; 46.7%)	29.9% (23.3%; 38.5%)	17.5% (10.6%; 29.0%)
	75+	225	39.4% (33.3%; 46.8%)	17.6% (12.7%; 24.6%)	18.1% (12.5%; 26.1%)	12.8% (6.6%; 24.7%)
Flanders	All ages	2,938	49.0% (47.2%; 51.0%)	27.7% (25.9%; 29.5%)	20.6% (18.9%; 22.5%)	18.2% (15.7%; 21.0%)
	15-59	429	66.2% (61.8%; 70.9%)	44.8% (40.2%; 49.9%)	34.1% (29.5%; 39.3%)	29.2% (24.4%; 34.8%)
	60-74	1,092	56.8% (53.9%; 59.9%)	31.0% (28.3%; 34.1%)	23.4% (20.7%; 26.4%)	19.4% (16.2%; 23.3%)
	75+	1,417	37.9% (35.3%; 40.6%)	19.9% (17.6%; 22.5%)	14.4% (12.0%; 17.3%)	14.7% (10.1%; 21.4%)
Wallonia	All ages	1,756	50.6% (48.3%; 53.1%)	29.6% (27.3%; 32.0%)	21.6% (19.3%; 24.1%)	16.5% (12.2%; 22.3%)
	15-59	257	66.3% (60.8%; 72.3%)	40.2% (34.5%; 46.8%)	29.9% (24.4%; 36.6%)	28.3% (22.6%; 35.6%)
	60-74	744	56.5% (53.0%; 60.2%)	33.6% (30.2%; 37.5%)	26.3% (22.9%; 30.2%)	19.9% (16.2%; 24.5%)
	75+	755	39.5% (36.0%; 43.3%)	22.0% (18.8%; 25.8%)	14.4% (11.3%; 18.4%)	9.7% (4.2%; 22.7%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2. Cancer of the biliary system survival: by tumour type

4.2.1. Cancer of the biliary system survival by type and sex: number at risk and net survival probabilities, 2014-2023

type	Net Survival Probability, 2014-2023						
	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	15,062	52.0% (51.2%; 52.9%)	37.6% (36.8%; 38.4%)	30.3% (29.5%; 31.1%)	25.8% (25.0%; 26.7%)	22.5% (21.7%; 23.4%)	16.2% (14.9%; 17.7%)
Males							
Cholangiocarcinoma	2,025	44.1% (41.9%; 46.4%)	26.6% (24.7%; 28.8%)	18.8% (17.0%; 20.8%)	14.4% (12.7%; 16.3%)	11.9% (10.3%; 13.9%)	6.4% (4.4%; 9.4%)
Hepatocellular carcinoma	5,716	57.3% (56.0%; 58.7%)	43.6% (42.3%; 45.0%)	36.1% (34.7%; 37.5%)	31.3% (29.9%; 32.8%)	26.6% (25.2%; 28.2%)	16.5% (14.5%; 18.9%)
Adenocarcinoma	1,489	58.2% (55.7%; 60.9%)	42.9% (40.3%; 45.7%)	34.1% (31.5%; 37.0%)	30.6% (28.0%; 33.5%)	28.1% (25.4%; 31.1%)	24.7% (20.9%; 29.3%)
Other and unspecified	661	33.9% (30.3%; 37.9%)	23.3% (20.0%; 27.1%)	21.0% (17.7%; 24.8%)	17.2% (14.0%; 21.2%)	16.0% (12.6%; 20.3%)	12.8% (8.0%; 20.4%)
Females							
Cholangiocarcinoma	1,583	47.6% (45.1%; 50.2%)	29.3% (27.0%; 31.7%)	20.2% (18.2%; 22.5%)	14.9% (13.0%; 17.0%)	12.0% (10.2%; 14.2%)	8.8% (6.6%; 11.7%)
Hepatocellular carcinoma	1,558	57.1% (54.6%; 59.7%)	44.9% (42.3%; 47.6%)	38.4% (35.9%; 41.2%)	32.6% (30.0%; 35.4%)	29.5% (26.9%; 32.4%)	22.1% (18.7%; 26.1%)
Adenocarcinoma	1,406	54.0% (51.3%; 56.8%)	38.5% (35.8%; 41.3%)	31.4% (28.8%; 34.2%)	28.0% (25.3%; 30.9%)	25.2% (22.5%; 28.3%)	20.6% (15.2%; 27.8%)
Other and unspecified	649	29.2% (25.8%; 33.1%)	21.3% (18.2%; 25.0%)	18.0% (15.0%; 21.7%)	15.6% (12.6%; 19.4%)	14.4% (11.2%; 18.5%)	16.3% (11.4%; 23.2%)

4.3. Cancer of the biliary system survival: by tumour location and tumour type and tumour stage

4.3.1. Cancer of the biliary system survival by location, type, stage and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023														
type	Stage	N at risk	1-y (95%CI)		2-y (95%CI)		3-y (95%CI)		4-y (95%CI)		5-y (95%CI)		10-y (95%CI)	
Total		15,062	52.0%	(51.2%; 52.9%)	37.6%	(36.8%; 38.4%)	30.3%	(29.5%; 31.1%)	25.8%	(25.0%; 26.7%)	22.5%	(21.7%; 23.4%)	16.2%	(14.9%; 17.7%)
Males														
Hepatic Cholangiocarcinoma	All	1,363	41.1%	(38.5%; 43.9%)	23.2%	(21.0%; 25.7%)	16.4%	(14.3%; 18.7%)	11.8%	(9.9%; 14.0%)	9.6%	(7.8%; 11.8%)	6.2%	(4.3%; 9.0%)
	I	148	77.8%	(70.9%; 85.4%)	60.8%	(52.8%; 70.1%)	53.7%	(45.2%; 63.9%)	49.4%	(40.5%; 60.2%)	39.2%	(30.0%; 51.1%)	30.6%	(20.4%; 45.9%)
	II	172	60.3%	(53.2%; 68.3%)	38.4%	(31.4%; 46.9%)	33.0%	(26.1%; 41.8%)	25.1%	(18.4%; 34.3%)	17.8%	(11.4%; 27.7%)	10.0%	(4.3%; 23.6%)
	III	145	46.3%	(38.7%; 55.4%)	27.5%	(20.9%; 36.2%)	13.3%	(8.3%; 21.4%)	8.6%	(4.3%; 17.4%)	8.8%	(4.4%; 17.8%)	FU<10y	
	IV	728	29.6%	(26.4%; 33.1%)	11.9%	(9.6%; 14.6%)	6.0%	(4.3%; 8.2%)	2.4%	(1.4%; 4.2%)	2.1%	(1.1%; 3.8%)	FU<10y	
	X/NA	170	35.0%	(28.4%; 43.1%)	20.2%	(14.9%; 27.6%)	13.8%	(9.2%; 20.6%)	9.1%	(5.5%; 15.2%)	8.7%	(5.1%; 14.7%)	FU<10y	
Cholangiocarcinoma of gallbladder & biliary tract	All	663	50.1%	(46.3%; 54.2%)	33.6%	(30.0%; 37.7%)	23.7%	(20.3%; 27.7%)	19.6%	(16.3%; 23.6%)	16.7%	(13.4%; 20.7%)	7.4%	(3.8%; 14.1%)
Hepatocellular carcinoma	All	5,716	57.3%	(56.0%; 58.7%)	43.6%	(42.3%; 45.0%)	36.1%	(34.7%; 37.5%)	31.3%	(29.9%; 32.8%)	26.6%	(25.2%; 28.2%)	16.5%	(14.5%; 18.9%)
	I	1,204	85.3%	(83.1%; 87.5%)	74.2%	(71.4%; 77.1%)	66.1%	(62.9%; 69.4%)	59.8%	(56.3%; 63.5%)	50.9%	(46.8%; 55.3%)	34.4%	(27.7%; 42.8%)
	II	1,099	73.3%	(70.6%; 76.1%)	57.4%	(54.3%; 60.6%)	46.8%	(43.6%; 50.3%)	39.8%	(36.5%; 43.5%)	36.7%	(33.2%; 40.6%)	23.7%	(18.4%; 30.6%)
	III	997	40.7%	(37.7%; 44.0%)	26.7%	(23.9%; 29.8%)	20.2%	(17.5%; 23.2%)	17.6%	(15.0%; 20.7%)	13.7%	(11.1%; 17.0%)	4.4%	(1.6%; 12.1%)
	IV	990	23.2%	(20.7%; 26.1%)	11.0%	(9.1%; 13.3%)	7.3%	(5.7%; 9.3%)	5.0%	(3.6%; 7.0%)	3.7%	(2.4%; 5.7%)	FU<10y	
	X/NA	1,426	56.7%	(54.1%; 59.4%)	41.7%	(39.0%; 44.5%)	33.7%	(31.1%; 36.5%)	28.7%	(26.1%; 31.4%)	23.5%	(21.0%; 26.3%)	14.3%	(11.7%; 17.5%)
Adenocarcinoma of gallbladder & biliary tract	All	1,312	59.7%	(57.0%; 62.6%)	44.0%	(41.2%; 47.0%)	35.0%	(32.2%; 38.1%)	31.8%	(28.9%; 35.0%)	29.6%	(26.6%; 32.9%)	26.9%	(22.6%; 32.0%)
	I	166	92.2%	(87.0%; 97.6%)	82.8%	(75.5%; 90.8%)	73.3%	(64.5%; 83.2%)	70.8%	(61.4%; 81.7%)	69.9%	(59.8%; 81.7%)	64.5%	(47.5%; 87.6%)
	II	172	84.3%	(78.3%; 90.8%)	74.6%	(67.2%; 82.9%)	64.2%	(55.7%; 74.0%)	58.6%	(49.5%; 69.3%)	51.2%	(41.3%; 63.3%)	56.2%	(43.9%; 72.0%)
	III	252	77.5%	(72.2%; 83.2%)	61.3%	(55.1%; 68.2%)	48.9%	(42.4%; 56.4%)	44.1%	(37.4%; 52.0%)	41.4%	(34.5%; 49.7%)	35.9%	(24.4%; 53.0%)
	IV	201	35.4%	(29.2%; 42.8%)	15.9%	(11.4%; 22.1%)	5.8%	(3.1%; 10.7%)	6.0%	(3.2%; 11.1%)	6.2%	(3.3%; 11.5%)	FU<10y	

Net Survival Probability, 2014-2023												
type	Stage	N at risk	1-y (95%CI)		2-y (95%CI)		3-y (95%CI)		4-y (95%CI)		5-y (95%CI)	10-y (95%CI)
	X/NA	524	42.1%	(37.9%; 46.7%)	24.4%	(20.8%; 28.7%)	18.0%	(14.7%; 21.9%)	15.0%	(11.9%; 18.9%)	13.5% (10.5%; 17.4%)	11.5% (7.8%; 17.1%)
Other and unspecified	All	838	36.7%	(33.5%; 40.3%)	25.7%	(22.7%; 29.1%)	22.3%	(19.4%; 25.8%)	18.2%	(15.3%; 21.7%)	16.3% (13.3%; 19.9%)	12.3% (8.4%; 18.0%)
	I	59	72.3%	(60.9%; 85.9%)	63.3%	(50.8%; 78.8%)	57.3%	(44.3%; 74.2%)	42.8%	(28.9%; 63.4%)	37.6% (24.1%; 58.6%)	FU<10y
	II	63	59.0%	(47.6%; 73.2%)	46.4%	(34.9%; 61.7%)	36.1%	(25.1%; 52.0%)	29.0%	(18.5%; 45.4%)	28.6% (17.9%; 45.7%)	32.1% (18.6%; 55.3%)
	III	84	37.6%	(28.4%; 49.9%)	28.0%	(19.5%; 40.4%)	24.8%	(16.4%; 37.5%)	22.0%	(13.6%; 35.8%)	17.1% (8.9%; 33.0%)	10.1% (2.4%; 41.9%)
	IV	210	21.1%	(16.2%; 27.5%)	12.1%	(8.3%; 17.6%)	11.4%	(7.6%; 17.1%)	9.0%	(5.5%; 14.8%)	5.5% (2.6%; 11.6%)	4.1% (1.4%; 11.8%)
	X/NA	422	36.0%	(31.5%; 41.1%)	23.9%	(19.8%; 28.8%)	20.5%	(16.6%; 25.4%)	17.1%	(13.2%; 22.1%)	16.3% (12.4%; 21.6%)	10.9% (6.3%; 18.9%)
Females												
Hepatic Cholangiocarcinoma	All	1,120	48.5%	(45.6%; 51.6%)	29.7%	(27.0%; 32.6%)	20.9%	(18.5%; 23.7%)	15.2%	(13.0%; 17.9%)	12.0% (9.8%; 14.6%)	7.6% (5.3%; 10.9%)
	I	117	82.6%	(75.5%; 90.3%)	68.1%	(59.3%; 78.2%)	61.8%	(52.5%; 72.9%)	52.6%	(42.7%; 64.9%)	45.4% (35.1%; 58.9%)	30.0% (17.8%; 50.7%)
	II	123	73.0%	(65.2%; 81.6%)	52.0%	(43.5%; 62.2%)	46.7%	(38.0%; 57.3%)	41.3%	(32.4%; 52.5%)	29.1% (19.9%; 42.4%)	FU<10y
	III	125	53.6%	(45.3%; 63.5%)	33.9%	(26.0%; 44.2%)	22.5%	(15.7%; 32.2%)	16.5%	(10.5%; 26.1%)	15.3% (9.3%; 25.2%)	FU<10y
	IV	609	38.2%	(34.5%; 42.3%)	18.0%	(15.1%; 21.5%)	8.0%	(6.0%; 10.7%)	4.1%	(2.6%; 6.3%)	2.7% (1.5%; 4.8%)	1.4% (0.6%; 3.5%)
	X/NA	146	39.3%	(32.0%; 48.3%)	25.5%	(19.0%; 34.1%)	19.6%	(13.7%; 27.9%)	9.7%	(5.6%; 17.0%)	7.2% (3.6%; 14.1%)	FU<10y
Cholangiocarcinoma of gallbladder & biliary tract	All	465	45.5%	(41.0%; 50.4%)	28.3%	(24.3%; 32.9%)	18.8%	(15.3%; 23.1%)	14.1%	(10.9%; 18.2%)	12.3% (9.1%; 16.6%)	11.6% (7.3%; 18.4%)
Hepatocellular carcinoma	All	1,558	57.1%	(54.6%; 59.7%)	44.9%	(42.3%; 47.6%)	38.4%	(35.9%; 41.2%)	32.6%	(30.0%; 35.4%)	29.5% (26.9%; 32.4%)	22.1% (18.7%; 26.1%)
	I	374	83.5%	(79.6%; 87.7%)	72.2%	(67.4%; 77.3%)	65.3%	(60.0%; 71.1%)	60.0%	(54.4%; 66.3%)	55.1% (49.1%; 61.9%)	45.6% (36.2%; 57.5%)
	II	276	74.4%	(69.2%; 80.1%)	62.4%	(56.5%; 69.0%)	54.9%	(48.7%; 62.0%)	44.4%	(37.7%; 52.2%)	37.9% (31.0%; 46.2%)	25.9% (18.3%; 36.7%)
	III	258	36.9%	(31.4%; 43.4%)	25.6%	(20.7%; 31.8%)	19.8%	(15.2%; 25.7%)	15.1%	(10.9%; 21.1%)	14.8% (10.5%; 20.8%)	FU<10y
	IV	255	24.1%	(19.3%; 30.1%)	13.0%	(9.3%; 18.1%)	9.4%	(6.1%; 14.2%)	6.5%	(3.8%; 11.1%)	4.2% (2.0%; 8.6%)	FU<10y
	X/NA	395	54.5%	(49.7%; 59.8%)	39.9%	(35.1%; 45.3%)	32.5%	(27.9%; 37.9%)	26.8%	(22.4%; 32.0%)	25.2% (20.8%; 30.6%)	18.2% (13.5%; 24.6%)
Adenocarcinoma of gallbladder & biliary tract	All	1,318	54.1%	(51.3%; 56.9%)	38.3%	(35.6%; 41.2%)	31.3%	(28.6%; 34.2%)	28.1%	(25.3%; 31.1%)	25.4% (22.5%; 28.6%)	21.4% (15.7%; 29.2%)
	I	143	90.0%	(84.4%; 96.0%)	84.1%	(76.8%; 92.1%)	79.7%	(71.3%; 89.0%)	78.6%	(69.4%; 88.9%)	73.9% (63.3%; 86.4%)	57.0% (33.8%; 96.3%)
	II	203	83.8%	(78.4%; 89.6%)	67.8%	(61.1%; 75.4%)	59.5%	(52.1%; 68.0%)	57.1%	(49.3%; 66.2%)	55.2% (46.8%; 65.1%)	35.6% (19.8%; 63.8%)

Net Survival Probability, 2014-2023										
type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)		
	III	259	63.3% (57.4%; 69.7%)	46.5% (40.4%; 53.5%)	35.0% (28.9%; 42.2%)	28.0% (22.1%; 35.5%)	24.6% (18.5%; 32.8%)	31.5% (21.0%; 47.1%)		
	IV	290	32.3% (27.3%; 38.3%)	13.6% (10.1%; 18.3%)	10.0% (6.9%; 14.6%)	7.5% (4.7%; 12.1%)	6.0% (3.4%; 10.6%)	FU<10y		
	X/NA	423	36.9% (32.4%; 42.0%)	20.7% (17.0%; 25.3%)	13.9% (10.8%; 18.0%)	11.2% (8.2%; 15.3%)	8.6% (5.9%; 12.7%)	9.8% (6.5%; 14.8%)		
Other and unspecified	All	735	32.0% (28.7%; 35.7%)	23.5% (20.4%; 27.0%)	19.7% (16.7%; 23.2%)	16.9% (14.0%; 20.4%)	15.4% (12.4%; 19.1%)	15.6% (11.4%; 21.4%)		
	I	45	N<50	N<50	N<50	N<50	N<50	N<50		
	II	57	54.8% (42.9%; 69.9%)	48.4% (36.3%; 64.5%)	42.0% (29.9%; 59.0%)	36.1% (23.6%; 55.3%)	29.2% (16.5%; 51.6%)	FU<10y		
	III	63	32.4% (22.5%; 46.7%)	19.7% (11.9%; 32.7%)	18.3% (10.7%; 31.3%)	16.8% (9.4%; 29.8%)	17.2% (9.7%; 30.5%)	13.2% (5.8%; 30.0%)		
	IV	213	18.8% (14.2%; 25.0%)	9.0% (5.9%; 14.0%)	7.6% (4.7%; 12.4%)	5.5% (3.1%; 9.9%)	5.7% (3.2%; 10.2%)	2.9% (1.1%; 7.7%)		
	X/NA	357	31.2% (26.6%; 36.7%)	22.5% (18.2%; 27.8%)	19.6% (15.4%; 24.9%)	16.6% (12.5%; 21.9%)	15.0% (10.8%; 20.9%)	20.2% (13.1%; 31.0%)		

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

5. CANCER SURVIVAL TRENDS



5.1. Cancer of the biliary system survival trends: by tumour type

5.1.1. Cancer of the biliary system survival trends by type and sex: number at risk and net survival probabilities, 2004-2023

type	Period	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Total	2004-2008	2,463	49.5% (47.5%; 51.6%)	27.9% (26.0%; 29.8%)	21.1% (19.4%; 23.0%)	1,637	46.4% (44.0%; 49.0%)	25.7% (23.5%; 28.1%)	19.8% (17.8%; 22.1%)
	2009-2013	3,555	50.6% (49.0%; 52.4%)	28.4% (26.8%; 30.0%)	21.0% (19.6%; 22.6%)	2,149	47.6% (45.5%; 49.8%)	25.0% (23.1%; 27.0%)	18.7% (16.9%; 20.6%)
	2014-2018	4,513	52.6% (51.1%; 54.1%)	30.7% (29.3%; 32.2%)	22.9% (21.5%; 24.3%)	2,451	49.2% (47.2%; 51.3%)	28.1% (26.2%; 30.0%)	21.2% (19.5%; 23.1%)
	2019-2023	5,364	53.7% (52.3%; 55.1%)	31.7% (30.2%; 33.1%)	23.4% (21.8%; 25.2%)	2,738	50.4% (48.5%; 52.4%)	28.9% (27.1%; 30.9%)	21.1% (18.9%; 23.4%)
Cholangiocarcinoma	2004-2008	456	45.5% (41.0%; 50.4%)	18.7% (15.3%; 22.9%)	12.7% (9.8%; 16.5%)	375	43.5% (38.7%; 49.0%)	18.7% (15.0%; 23.3%)	11.3% (8.4%; 15.3%)
	2009-2013	675	47.9% (44.1%; 51.9%)	20.1% (17.1%; 23.6%)	11.7% (9.3%; 14.7%)	533	42.4% (38.4%; 46.9%)	16.4% (13.5%; 20.0%)	8.7% (6.6%; 11.7%)
	2014-2018	780	44.7% (41.3%; 48.5%)	20.1% (17.3%; 23.3%)	13.0% (10.7%; 15.9%)	642	49.0% (45.2%; 53.2%)	21.3% (18.3%; 24.9%)	13.9% (11.2%; 17.1%)
	2019-2023	1,245	43.7% (40.9%; 46.6%)	17.8% (15.5%; 20.5%)	10.8% (8.4%; 13.9%)	941	46.6% (43.5%; 50.0%)	19.4% (16.7%; 22.5%)	8.7% (5.9%; 12.7%)
Hepatocellular carcinoma	2004-2008	1,294	50.2% (47.5%; 53.1%)	30.8% (28.2%; 33.6%)	22.8% (20.4%; 25.5%)	434	53.4% (48.8%; 58.4%)	33.8% (29.3%; 38.8%)	25.9% (21.7%; 30.8%)
	2009-2013	2,046	52.6% (50.4%; 54.9%)	31.0% (28.9%; 33.2%)	23.3% (21.4%; 25.5%)	652	53.5% (49.7%; 57.6%)	34.2% (30.6%; 38.4%)	25.5% (22.0%; 29.5%)
	2014-2018	2,673	55.3% (53.4%; 57.3%)	34.2% (32.3%; 36.3%)	25.6% (23.7%; 27.6%)	752	55.0% (51.5%; 58.8%)	37.2% (33.7%; 41.1%)	29.2% (25.8%; 33.0%)
	2019-2023	3,043	59.1% (57.3%; 60.9%)	37.7% (35.7%; 39.7%)	27.2% (24.9%; 29.7%)	806	59.1% (55.7%; 62.7%)	39.8% (36.2%; 43.8%)	29.7% (25.6%; 34.4%)

type	Period	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Adenocarcinoma	2004-2008	551	56.1% (51.9%; 60.6%)	31.2% (27.2%; 35.7%)	25.3% (21.4%; 29.9%)	650	46.4% (42.6%; 50.5%)	26.6% (23.1%; 30.7%)	22.3% (18.9%; 26.3%)
	2009-2013	594	52.9% (48.9%; 57.3%)	32.1% (28.2%; 36.5%)	24.6% (20.9%; 29.0%)	689	52.8% (49.1%; 56.8%)	26.5% (23.2%; 30.4%)	22.3% (19.0%; 26.2%)
	2014-2018	767	58.1% (54.5%; 61.9%)	33.0% (29.5%; 36.8%)	25.8% (22.4%; 29.6%)	734	52.8% (49.1%; 56.7%)	28.5% (25.1%; 32.2%)	21.9% (18.7%; 25.7%)
	2019-2023	722	58.4% (54.7%; 62.3%)	35.5% (31.6%; 39.8%)	32.0% (27.6%; 37.2%)	672	55.3% (51.6%; 59.4%)	35.3% (31.4%; 39.6%)	31.2% (26.6%; 36.6%)
Other and unspecified	2004-2008	162	33.5% (26.8%; 41.8%)	19.1% (13.4%; 27.0%)	17.6% (12.0%; 25.8%)	178	35.8% (29.2%; 43.8%)	17.6% (12.5%; 24.7%)	14.1% (9.1%; 21.8%)
	2009-2013	246	36.9% (31.2%; 43.8%)	21.2% (16.3%; 27.6%)	19.1% (14.1%; 25.9%)	275	30.5% (25.4%; 36.7%)	15.8% (11.6%; 21.6%)	12.6% (8.6%; 18.6%)
	2014-2018	302	34.2% (29.0%; 40.2%)	21.7% (16.9%; 27.7%)	17.4% (12.6%; 24.0%)	325	28.1% (23.5%; 33.7%)	19.1% (14.8%; 24.5%)	15.5% (11.2%; 21.4%)
	2019-2023	359	33.7% (28.9%; 39.2%)	20.5% (16.3%; 25.8%)	14.7% (10.5%; 20.6%)	324	30.3% (25.6%; 36.0%)	16.7% (12.6%; 22.2%)	12.8% (8.5%; 19.3%)

5.2. Cancer of the biliary system survival trends: by tumour location and tumour type and tumour stage

5.2.1. Cancer of the biliary system survival trends by location, type, stage and sex: number at risk and net survival probabilities, 2004-2023

location	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Hepatic Cholangiocarcinoma	2004-2008	All	253	40.4% (34.7%; 47.1%)	17.4% (13.1%; 23.0%)	10.7% (7.3%; 15.7%)	210	45.0% (38.7%; 52.4%)	22.2% (17.1%; 28.8%)	13.9% (9.7%; 19.8%)
		I	18	N<50	N<50	N<50	11	N<50	N<50	N<50
		II	14	N<50	N<50	N<50	13	N<50	N<50	N<50
		III	55	50.7% (38.9%; 66.1%)	21.0% (12.3%; 36.0%)	10.2% (4.6%; 22.7%)	59	58.5% (47.1%; 72.7%)	28.3% (18.7%; 42.8%)	21.5% (12.9%; 35.9%)
		IV	54	24.4% (15.3%; 38.9%)	5.9% (2.1%; 16.2%)	2.1% (0.4%; 9.9%)	55	33.2% (22.9%; 48.1%)	11.1% (5.4%; 22.9%)	5.5% (2.0%; 15.4%)
		X/NA	112	29.1% (21.7%; 39.0%)	11.8% (6.9%; 20.0%)	5.3% (2.3%; 12.1%)	72	31.4% (22.3%; 44.3%)	14.6% (8.2%; 25.9%)	3.5% (1.1%; 11.5%)
	2009-2013	All	384	43.2% (38.4%; 48.6%)	17.8% (14.2%; 22.3%)	10.7% (7.9%; 14.6%)	318	42.0% (36.8%; 47.8%)	17.4% (13.6%; 22.3%)	8.4% (5.8%; 12.3%)
		I	23	N<50	N<50	N<50	15	N<50	N<50	N<50
		II	38	N<50	N<50	N<50	31	N<50	N<50	N<50
		III	30	N<50	N<50	N<50	29	N<50	N<50	N<50
		IV	165	38.6% (31.7%; 46.9%)	8.4% (5.0%; 14.2%)	6.2% (3.3%; 11.5%)	142	35.6% (28.5%; 44.4%)	16.0% (11.0%; 23.4%)	6.1% (3.2%; 11.7%)
		X/NA	128	24.9% (18.3%; 33.7%)	9.4% (5.4%; 16.3%)	3.9% (1.6%; 9.6%)	101	31.8% (23.8%; 42.5%)	6.5% (3.1%; 13.9%)	3.9% (1.5%; 10.5%)
	2014-2018	All	533	41.5% (37.4%; 46.0%)	17.3% (14.2%; 21.0%)	9.8% (7.4%; 13.0%)	465	49.8% (45.4%; 54.7%)	22.4% (18.7%; 26.7%)	14.0% (11.0%; 17.9%)
		I	52	82.4% (71.9%; 94.4%)	69.6% (57.0%; 85.0%)	48.7% (35.7%; 66.6%)	42	N<50	N<50	N<50
		II	52	63.5% (51.3%; 78.5%)	36.0% (24.4%; 53.0%)	15.0% (7.5%; 30.0%)	49	N<50	N<50	N<50
		III	36	N<50	N<50	N<50	41	N<50	N<50	N<50
		IV	273	29.5% (24.5%; 35.5%)	6.4% (4.0%; 10.3%)	3.2% (1.6%; 6.4%)	225	42.4% (36.3%; 49.5%)	9.6% (6.4%; 14.4%)	2.9% (1.4%; 6.1%)
		X/NA	120	37.7% (29.9%; 47.7%)	12.4% (7.5%; 20.4%)	7.5% (3.9%; 14.5%)	108	38.2% (29.9%; 48.8%)	17.8% (11.7%; 27.3%)	7.1% (3.4%; 14.6%)
	2019-2023	All	830	40.9% (37.6%; 44.5%)	15.8% (13.2%; 18.9%)	9.8% (7.0%; 13.6%)	655	47.6% (43.8%; 51.7%)	19.5% (16.3%; 23.2%)	8.0% (5.0%; 12.9%)
		I	96	75.3% (66.6%; 85.1%)	43.4% (32.8%; 57.4%)	36.4% (23.6%; 56.2%)	75	78.3% (69.0%; 89.0%)	59.9% (48.0%; 74.6%)	25.8% (12.0%; 55.3%)

location	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	120	58.9% (50.5%; 68.7%)	31.9% (23.9%; 42.6%)	21.0% (11.8%; 37.2%)	74	75.8% (66.2%; 86.8%)	48.5% (37.4%; 62.9%)	20.1% (8.6%; 46.9%)
		III	109	43.6% (35.0%; 54.2%)	13.4% (7.7%; 23.4%)	14.2% (8.1%; 24.7%)	84	51.8% (41.9%; 64.1%)	15.5% (8.9%; 27.0%)	4.5% (1.2%; 16.9%)
		IV	455	29.6% (25.6%; 34.2%)	5.6% (3.6%; 8.8%)	0.9% (0.3%; 2.9%)	384	35.7% (31.2%; 40.9%)	6.8% (4.4%; 10.3%)	2.8% (1.2%; 6.4%)
		X/NA	50	28.6% (18.4%; 44.3%)	18.2% (9.9%; 33.5%)	12.5% (5.6%; 28.0%)	38	N<50	N<50	N<50
Cholangiocarcinoma of gallbladder & biliary tract	2004-2008	All	204	52.0% (45.4%; 59.6%)	20.4% (15.3%; 27.1%)	15.1% (10.6%; 21.5%)	165	41.6% (34.6%; 50.1%)	14.3% (9.7%; 21.0%)	8.2% (4.8%; 14.0%)
	2009-2013	All	292	53.8% (48.2%; 60.1%)	23.1% (18.5%; 28.9%)	12.9% (9.3%; 18.1%)	215	43.1% (36.9%; 50.4%)	14.9% (10.7%; 20.7%)	9.3% (6.0%; 14.4%)
	2014-2018	All	247	51.7% (45.7%; 58.6%)	26.0% (20.8%; 32.6%)	19.9% (15.1%; 26.3%)	178	47.3% (40.4%; 55.5%)	19.1% (13.9%; 26.2%)	14.0% (9.4%; 20.6%)
	2019-2023	All	416	49.2% (44.4%; 54.4%)	21.9% (17.6%; 27.2%)	12.8% (8.6%; 19.0%)	287	44.3% (38.8%; 50.6%)	19.1% (14.6%; 24.9%)	10.2% (5.6%; 18.3%)
Hepatocellular carcinoma	2004-2008	All	1,294	50.2% (47.5%; 53.1%)	30.8% (28.2%; 33.6%)	22.8% (20.4%; 25.5%)	434	53.4% (48.8%; 58.4%)	33.8% (29.3%; 38.8%)	25.9% (21.7%; 30.8%)
		I	122	81.5% (74.5%; 89.2%)	71.1% (62.6%; 80.9%)	63.6% (54.1%; 74.9%)	60	83.7% (74.2%; 94.3%)	66.9% (54.9%; 81.6%)	59.0% (46.3%; 75.1%)
		II	215	76.0% (70.2%; 82.2%)	56.7% (50.0%; 64.3%)	47.9% (40.9%; 56.0%)	64	76.5% (66.5%; 88.0%)	51.5% (40.1%; 66.2%)	42.1% (30.7%; 57.8%)
		III	230	44.3% (38.2%; 51.4%)	20.0% (15.2%; 26.3%)	12.6% (8.7%; 18.3%)	79	47.6% (37.6%; 60.3%)	23.5% (15.5%; 35.6%)	16.0% (9.3%; 27.6%)
		IV	127	20.1% (14.2%; 28.5%)	9.3% (5.3%; 16.1%)	3.5% (1.4%; 9.0%)	41	N<50	N<50	N<50
		X/NA	600	43.2% (39.3%; 47.4%)	22.0% (18.7%; 25.8%)	13.6% (10.9%; 17.0%)	190	44.6% (37.9%; 52.5%)	27.7% (21.8%; 35.4%)	19.1% (13.9%; 26.2%)
	2009-2013	All	2,046	52.6% (50.4%; 54.9%)	31.0% (28.9%; 33.2%)	23.3% (21.4%; 25.5%)	652	53.5% (49.7%; 57.6%)	34.2% (30.6%; 38.4%)	25.5% (22.0%; 29.5%)
		I	272	79.7% (74.7%; 85.0%)	60.2% (54.0%; 67.0%)	52.3% (45.7%; 59.7%)	112	84.0% (77.0%; 91.6%)	57.6% (48.4%; 68.5%)	43.2% (34.0%; 54.9%)
		II	331	72.4% (67.6%; 77.6%)	48.9% (43.4%; 55.1%)	39.3% (33.8%; 45.7%)	113	71.5% (63.4%; 80.7%)	54.5% (45.4%; 65.4%)	43.2% (33.9%; 55.2%)
		III	291	39.5% (34.2%; 45.7%)	17.6% (13.5%; 23.0%)	10.0% (6.8%; 14.8%)	72	35.8% (26.2%; 48.9%)	16.4% (9.4%; 28.4%)	14.1% (7.6%; 26.0%)
		IV	296	24.0% (19.5%; 29.5%)	6.8% (4.4%; 10.5%)	2.2% (1.0%; 4.7%)	91	21.2% (14.3%; 31.5%)	5.7% (2.5%; 12.9%)	4.7% (1.9%; 11.6%)
		X/NA	856	50.8% (47.4%; 54.3%)	27.7% (24.6%; 31.0%)	19.8% (17.1%; 23.0%)	264	49.0% (43.2%; 55.5%)	30.5% (25.1%; 37.0%)	20.7% (16.0%; 26.8%)
	2014-2018	All	2,673	55.3% (53.4%; 57.3%)	34.2% (32.3%; 36.3%)	25.6% (23.7%; 27.6%)	752	55.0% (51.5%; 58.8%)	37.2% (33.7%; 41.1%)	29.2% (25.8%; 33.0%)
		I	444	86.2% (82.7%; 89.8%)	66.2% (61.3%; 71.5%)	54.1% (48.5%; 60.4%)	152	82.6% (76.4%; 89.3%)	67.9% (60.0%; 76.8%)	59.5% (51.1%; 69.3%)
		II	424	71.2% (66.8%; 75.8%)	46.3% (41.4%; 51.8%)	37.6% (32.8%; 43.2%)	120	70.1% (62.1%; 79.1%)	54.5% (45.6%; 65.1%)	38.6% (29.8%; 50.0%)

location	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		III	390	37.4% (32.7%; 42.6%)	17.6% (13.9%; 22.2%)	11.9% (8.7%; 16.1%)	91	35.0% (26.4%; 46.5%)	12.8% (7.4%; 22.1%)	8.2% (4.0%; 16.6%)
		IV	397	18.7% (15.1%; 23.0%)	3.9% (2.4%; 6.5%)	2.2% (1.1%; 4.5%)	107	17.3% (11.4%; 26.2%)	6.0% (2.8%; 12.6%)	4.0% (1.6%; 10.2%)
		X/NA	1,018	56.4% (53.4%; 59.7%)	33.4% (30.4%; 36.8%)	22.4% (19.6%; 25.6%)	282	54.5% (48.8%; 60.8%)	33.0% (27.7%; 39.4%)	25.2% (20.2%; 31.5%)
	2019-2023	All	3,043	59.1% (57.3%; 60.9%)	37.7% (35.7%; 39.7%)	27.2% (24.9%; 29.7%)	806	59.1% (55.7%; 62.7%)	39.8% (36.2%; 43.8%)	29.7% (25.6%; 34.4%)
		I	760	84.7% (82.0%; 87.6%)	65.9% (61.8%; 70.3%)	46.4% (40.7%; 53.0%)	222	84.2% (79.2%; 89.6%)	63.4% (56.4%; 71.2%)	50.6% (41.9%; 61.3%)
		II	675	74.7% (71.3%; 78.2%)	46.7% (42.4%; 51.5%)	34.4% (29.1%; 40.6%)	156	77.8% (71.1%; 85.1%)	55.7% (47.3%; 65.6%)	35.7% (25.4%; 50.2%)
		III	607	42.8% (39.0%; 47.1%)	22.0% (18.5%; 26.1%)	14.1% (9.7%; 20.5%)	167	38.0% (31.2%; 46.3%)	24.1% (18.1%; 32.1%)	19.3% (13.2%; 28.0%)
		IV	593	26.3% (22.9%; 30.1%)	9.6% (7.3%; 12.7%)	4.1% (2.2%; 7.7%)	148	29.1% (22.5%; 37.5%)	12.3% (7.6%; 19.9%)	3.7% (1.2%; 11.0%)
		X/NA	408	57.4% (52.6%; 62.6%)	34.2% (29.4%; 39.7%)	28.0% (23.1%; 34.0%)	113	54.5% (45.8%; 64.7%)	31.2% (23.3%; 41.9%)	26.4% (18.1%; 38.3%)
Adenocarcinoma of gallbladder & biliary tract	2004-2008	All	506	56.2% (51.8%; 61.0%)	31.0% (26.9%; 35.8%)	25.8% (21.7%; 30.7%)	607	47.2% (43.2%; 51.5%)	26.4% (22.8%; 30.7%)	21.9% (18.4%; 26.1%)
		I	113	82.2% (74.6%; 90.4%)	62.7% (53.0%; 74.2%)	58.8% (48.0%; 72.1%)	149	73.3% (66.0%; 81.3%)	55.2% (46.7%; 65.4%)	51.2% (42.0%; 62.3%)
		II	123	68.6% (60.5%; 77.8%)	37.3% (29.2%; 47.7%)	30.6% (22.7%; 41.1%)	147	61.1% (53.4%; 69.8%)	29.4% (22.5%; 38.3%)	21.8% (15.6%; 30.4%)
		III	33	N<50	N<50	N<50	38	N<50	N<50	N<50
		IV	71	34.1% (24.6%; 47.5%)	11.0% (5.3%; 22.7%)	6.5% (2.5%; 16.7%)	101	13.1% (8.0%; 21.5%)	1.1% (0.2%; 5.1%)	FU<5y
		X/NA	166	35.3% (28.5%; 43.9%)	13.4% (8.7%; 20.6%)	9.0% (5.1%; 15.9%)	172	31.9% (25.4%; 40.1%)	15.4% (10.0%; 23.7%)	10.8% (6.4%; 18.2%)
	2009-2013	All	542	52.2% (48.0%; 56.8%)	32.1% (28.0%; 36.8%)	25.0% (21.1%; 29.7%)	660	51.9% (48.1%; 56.0%)	25.5% (22.2%; 29.4%)	21.5% (18.2%; 25.5%)
		I	77	82.4% (73.5%; 92.5%)	79.6% (68.6%; 92.3%)	71.4% (58.4%; 87.3%)	94	87.6% (80.3%; 95.6%)	71.2% (61.1%; 82.9%)	71.2% (60.2%; 84.2%)
		II	110	77.2% (69.2%; 86.1%)	50.2% (40.8%; 61.7%)	34.9% (25.7%; 47.3%)	115	75.9% (67.9%; 84.9%)	41.1% (32.2%; 52.4%)	32.0% (23.2%; 44.3%)
		III	57	50.7% (39.0%; 65.9%)	22.1% (13.3%; 36.6%)	13.4% (6.8%; 26.4%)	94	55.4% (45.8%; 66.9%)	21.5% (14.3%; 32.4%)	14.2% (8.1%; 24.8%)
		IV	75	23.9% (15.9%; 36.0%)	9.0% (4.3%; 18.8%)	1.8% (0.4%; 8.4%)	123	29.9% (22.8%; 39.4%)	6.3% (3.2%; 12.5%)	3.6% (1.4%; 9.4%)
		X/NA	223	39.2% (33.0%; 46.5%)	17.1% (12.4%; 23.5%)	14.9% (10.3%; 21.4%)	234	36.2% (30.4%; 43.1%)	11.5% (7.9%; 16.9%)	9.0% (5.7%; 14.3%)
	2014-2018	All	675	58.8% (55.0%; 62.8%)	33.1% (29.5%; 37.3%)	26.5% (22.9%; 30.7%)	696	51.6% (47.9%; 55.6%)	26.9% (23.6%; 30.7%)	20.8% (17.6%; 24.6%)
		I	73	94.5% (87.8%; 101.8%)	72.7% (60.7%; 87.1%)	66.8% (53.5%; 83.5%)	65	92.0% (84.5%; 100.2%)	85.0% (74.1%; 97.4%)	82.2% (69.3%; 97.6%)

location	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	90	79.6% (70.9%; 89.4%)	54.6% (44.1%; 67.7%)	37.2% (27.1%; 51.1%)	106	81.4% (73.8%; 89.8%)	54.6% (45.1%; 66.3%)	46.8% (36.9%; 59.4%)
		III	112	80.8% (73.2%; 89.1%)	50.3% (41.1%; 61.6%)	42.4% (33.0%; 54.5%)	122	57.5% (49.1%; 67.4%)	27.9% (20.6%; 37.8%)	16.4% (10.4%; 25.7%)
		IV	96	32.2% (24.0%; 43.2%)	5.6% (2.5%; 12.7%)	5.9% (2.6%; 13.4%)	134	30.5% (23.6%; 39.5%)	5.5% (2.7%; 11.1%)	3.0% (1.1%; 7.9%)
		X/NA	306	44.1% (38.7%; 50.3%)	19.7% (15.4%; 25.2%)	14.4% (10.5%; 19.7%)	269	37.8% (32.3%; 44.4%)	12.2% (8.7%; 17.2%)	6.6% (3.9%; 11.3%)
	2019-2023	All	637	60.7% (56.8%; 64.9%)	37.3% (33.1%; 42.0%)	34.2% (29.3%; 39.8%)	622	56.8% (52.9%; 61.0%)	37.2% (33.1%; 41.8%)	33.3% (28.4%; 39.1%)
		I	93	90.4% (83.0%; 98.4%)	74.0% (61.9%; 88.4%)	73.6% (59.0%; 91.8%)	78	88.4% (80.4%; 97.1%)	75.0% (63.1%; 89.2%)	62.9% (44.6%; 88.5%)
		II	82	89.6% (81.8%; 98.1%)	75.4% (62.6%; 90.8%)	74.3% (56.7%; 97.5%)	97	86.5% (79.2%; 94.5%)	66.3% (55.6%; 79.1%)	72.9% (61.1%; 86.9%)
		III	140	75.0% (67.7%; 83.0%)	48.1% (39.5%; 58.7%)	42.0% (32.7%; 53.8%)	137	68.4% (60.7%; 77.0%)	43.6% (34.9%; 54.5%)	40.3% (30.1%; 54.0%)
		IV	105	38.3% (29.9%; 49.0%)	6.2% (2.6%; 14.8%)	FU<5y	156	33.9% (27.1%; 42.3%)	14.7% (9.9%; 22.0%)	9.6% (5.0%; 18.3%)
		X/NA	218	39.2% (33.1%; 46.6%)	15.4% (11.0%; 21.7%)	11.8% (7.5%; 18.6%)	154	35.2% (28.2%; 43.9%)	17.3% (11.9%; 25.3%)	14.0% (8.8%; 22.2%)
Other and unspecified	2004-2008	All	206	37.7% (31.5%; 45.2%)	22.1% (16.7%; 29.2%)	18.0% (13.0%; 25.0%)	221	35.7% (29.7%; 42.8%)	19.8% (14.9%; 26.2%)	16.7% (11.8%; 23.5%)
		I	10	N<50	N<50	N<50	16	N<50	N<50	N<50
		II	17	N<50	N<50	N<50	21	N<50	N<50	N<50
		III	25	N<50	N<50	N<50	26	N<50	N<50	N<50
		IV	37	N<50	N<50	N<50	39	N<50	N<50	N<50
		X/NA	117	37.3% (29.3%; 47.5%)	23.8% (16.7%; 34.0%)	19.0% (12.5%; 29.0%)	119	42.1% (33.9%; 52.4%)	24.1% (17.1%; 33.9%)	20.2% (13.1%; 31.0%)
	2009-2013	All	297	41.2% (35.8%; 47.4%)	23.2% (18.5%; 29.0%)	19.4% (14.9%; 25.3%)	304	34.6% (29.5%; 40.6%)	19.1% (14.7%; 24.7%)	15.3% (11.1%; 21.0%)
		I	27	N<50	N<50	N<50	13	N<50	N<50	N<50
		II	29	N<50	N<50	N<50	17	N<50	N<50	N<50
		III	24	N<50	N<50	N<50	14	N<50	N<50	N<50
		IV	53	34.9% (24.1%; 50.5%)	18.1% (10.0%; 32.6%)	13.3% (6.5%; 27.2%)	74	21.0% (13.5%; 32.7%)	8.1% (3.7%; 17.7%)	6.3% (2.4%; 16.6%)
		X/NA	164	37.1% (30.2%; 45.7%)	20.3% (14.6%; 28.3%)	18.1% (12.2%; 26.7%)	186	35.1% (28.6%; 42.9%)	18.4% (13.0%; 26.0%)	14.0% (9.0%; 21.9%)
	2014-2018	All	394	38.6% (33.9%; 43.9%)	24.1% (19.8%; 29.3%)	18.0% (13.9%; 23.4%)	362	32.8% (28.1%; 38.2%)	22.8% (18.5%; 28.1%)	18.0% (13.7%; 23.6%)

location	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	21	N<50	N<50	N<50	24	N<50	N<50	N<50
		II	26	N<50	N<50	N<50	25	N<50	N<50	N<50
		III	25	N<50	N<50	N<50	20	N<50	N<50	N<50
		IV	76	23.2% (15.4%; 35.0%)	12.6% (6.8%; 23.6%)	4.6% (1.4%; 14.7%)	90	20.6% (13.6%; 31.1%)	9.7% (5.1%; 18.4%)	6.0% (2.6%; 13.8%)
		X/NA	246	37.8% (32.0%; 44.7%)	21.3% (16.3%; 28.0%)	17.3% (12.4%; 24.2%)	203	32.1% (26.1%; 39.6%)	22.9% (17.2%; 30.6%)	17.6% (11.9%; 25.9%)
2019-2023	All		444	35.0% (30.7%; 40.0%)	20.8% (16.9%; 25.5%)	14.7% (10.8%; 20.0%)	373	31.2% (26.7%; 36.5%)	16.4% (12.6%; 21.3%)	12.5% (8.6%; 18.1%)
	I		38	N<50	N<50	N<50	21	N<50	N<50	N<50
	II		37	N<50	N<50	N<50	32	N<50	N<50	N<50
	III		59	39.3% (28.4%; 54.4%)	27.1% (17.1%; 43.0%)	15.9% (7.2%; 35.1%)	43	N<50	N<50	N<50
	IV		134	19.9% (14.2%; 28.1%)	10.7% (6.4%; 17.8%)	7.2% (3.4%; 15.0%)	123	17.5% (11.9%; 25.8%)	6.2% (3.0%; 12.6%)	5.6% (2.6%; 12.1%)
	X/NA		176	33.5% (26.9%; 41.6%)	19.7% (14.0%; 27.7%)	15.3% (9.6%; 24.3%)	154	30.1% (23.4%; 38.6%)	14.5% (9.3%; 22.6%)	11.2% (6.1%; 20.7%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

6. CANCER MORTALITY



6.1. Cancer of the biliary system mortality: by region

6.1.1. *Cancer of the biliary system mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021*

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	0	0	0	0	1	1	2	5	3	5	19	45	68	125	139	140	106	75	23	3	760	14.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.5]	[1.3]	[0.8]	[1.3]	[4.8]	[11.2]	[18.7]	[40.8]	[52.4]	[80.4]	[81.1]	[96.5]	[81.9]	[55.0]	[13.4]	(13.8; 15.9)
Brussels	0	0	0	0	0	0	0	1	1	0	3	4	9	11	7	7	7	7	2	0	59	15.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[2.1]	[0.0]	[7.5]	[11.7]	[32.9]	[52.9]	[41.9]	[60.9]	[82.8]	[138.5]	[92.0]	[0.0]	[9.8]	(11.7; 20.0)
Flanders	0	0	0	0	0	1	1	3	1	3	6	22	24	56	61	85	66	48	11	2	390	12.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[1.4]	[0.5]	[1.4]	[2.6]	[9.0]	[10.9]	[29.8]	[37.7]	[74.4]	[76.5]	[92.8]	[60.0]	[55.9]	[11.8]	(10.9; 13.3)
Wallonia	0	0	0	0	1	0	1	1	1	2	10	19	35	58	71	48	33	20	10	1	311	20.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.8]	[0.9]	[0.9]	[1.6]	[8.1]	[15.2]	[30.5]	[59.3]	[82.2]	[98.9]	[91.8]	[95.5]	[132.0]	[71.1]	[17.4]	(17.7; 22.2)
Females																						
Belgium	0	0	0	0	1	3	2	3	1	4	15	12	36	54	68	75	86	65	40	11	476	7.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[0.5]	[0.8]	[0.3]	[1.1]	[3.9]	[3.0]	[9.7]	[16.6]	[22.9]	[35.2]	[46.5]	[48.1]	[60.4]	[57.2]	[8.1]	(6.6; 7.9)
Brussels	0	0	0	0	0	2	0	0	0	0	2	3	5	5	6	8	7	4	6	2	50	9.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.7]	[0.0]	[0.0]	[0.0]	[0.0]	[5.4]	[9.0]	[16.8]	[20.4]	[27.8]	[49.2]	[51.1]	[39.4]	[104.5]	[102.2]	[8.1]	(6.9; 12.3)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	0	0	1	1	1	2	1	1	6	8	16	28	36	43	54	38	23	7	266	6.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.6]	[0.5]	[0.5]	[1.0]	[0.5]	[0.5]	[2.6]	[3.3]	[7.2]	[14.5]	[20.7]	[32.3]	[46.5]	[44.7]	[57.4]	[62.3]	[7.9]	(5.8; 7.4)
Wallonia	0	0	0	0	0	0	1	1	0	3	7	1	15	21	26	24	25	23	11	2	160	7.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[0.0]	[2.4]	[5.6]	[0.8]	[12.4]	[19.3]	[25.8]	[37.7]	[45.3]	[57.4]	[53.9]	[33.1]	[8.6]	(6.6; 9.1)

7. CANCER MORTALITY TRENDS



7.1. Cancer of the biliary system mortality trends: by region

7.1.1. Cancer of the biliary system mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	476	468	473	503	533	513	549	586	598	604	596	671	669	657	675	684	698	760	1.0 (0.8; 1.3)	2004-2021
	CR	9.4	9.2	9.2	9.7	10.2	9.7	10.3	10.9	11.0	11.1	10.9	12.2	12.1	11.8	12.1	12.2	12.3	13.4		
	ESR2013	12.2	12.0	12.2	12.6	12.8	12.4	12.7	13.2	13.3	13.5	13.0	14.4	14.3	13.6	13.8	13.7	13.8	14.8		
Brussels	N	49	60	47	49	52	50	62	52	56	59	59	57	60	61	59	59	62	59	0.3 (-0.6; 1.1)	2004-2021
	CR	10.2	12.4	9.6	9.9	10.3	9.7	11.8	9.6	10.1	10.5	10.4	10.0	10.3	10.5	10.1	10.0	10.4	9.8		
	ESR2013	15.6	18.5	15.0	15.5	15.4	15.2	19.6	13.9	15.9	18.0	17.9	15.3	17.2	17.3	15.9	16.4	17.5	15.9		
Flanders	N	241	228	249	247	273	279	290	326	318	311	321	315	321	343	323	370	354	390	1.0 (0.6; 1.4) 2.4 (1.4; 3.4) -1.5 (-3.0; 0.0) 1.2 (0.0; 2.4)	2004-2021 2004-2011 2012-2015 2016-2021
	CR	8.1	7.7	8.3	8.2	9.0	9.1	9.4	10.5	10.1	9.9	10.1	9.9	10.0	10.6	10.0	11.3	10.8	11.8		
	ESR2013	10.1	10.0	10.4	10.3	10.9	11.0	10.9	12.1	11.6	11.2	11.3	11.0	11.1	11.4	10.7	12.0	11.1	12.1		
Wallonia	N	186	180	177	207	208	184	197	208	224	234	216	299	288	253	293	255	282	311	1.7 (0.8; 2.6)	2004-2021
	CR	11.3	10.9	10.7	12.4	12.4	10.9	11.6	12.1	13.0	13.5	12.4	17.1	16.4	14.3	16.6	14.4	15.8	17.4		
	ESR2013	15.1	14.3	15.2	16.4	16.1	14.5	14.7	15.0	16.2	16.9	15.0	21.3	19.9	17.4	19.8	16.5	18.2	20.0		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Cancer of the biliary system mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	374	374	394	395	403	433	450	456	424	446	420	431	410	428	388	475	419	476		
	CR	7.0	7.0	7.3	7.3	7.4	7.9	8.1	8.2	7.5	7.9	7.4	7.6	7.2	7.4	6.7	8.2	7.2	8.1		
	ESR2013	7.0	6.9	7.1	6.9	7.0	7.5	7.8	7.6	6.9	7.3	6.8	6.8	6.4	6.7	6.0	7.2	6.3	7.2	0.0 (-0.6; 0.6)	2004-2021
																				1.5 (-0.1; 3.1)	2004-2011
																				-3.7 (-6.0; -1.3)	2012-2015
																				0.7 (-1.2; 2.6)	2016-2021
Brussels	N	35	33	58	38	53	30	53	46	52	38	41	51	39	42	32	43	28	50		
	CR	6.7	6.3	11.0	7.1	9.8	5.4	9.4	8.0	8.9	6.4	6.9	8.5	6.4	6.9	5.2	7.0	4.5	8.1		
	ESR2013	6.6	6.2	11.1	7.6	10.4	5.8	10.3	9.3	9.5	7.5	8.1	10.3	7.7	7.7	5.7	8.0	5.4	9.6	-0.5 (-2.6; 1.8)	2004-2021
Flanders	N	198	220	211	201	205	261	235	243	221	259	235	229	223	231	241	280	244	266		
	CR	6.5	7.2	6.8	6.5	6.6	8.3	7.4	7.6	6.9	8.0	7.2	7.0	6.8	7.0	7.3	8.4	7.3	7.9		
	ESR2013	6.5	7.1	6.6	6.1	6.1	7.7	7.0	6.8	6.2	7.2	6.4	6.0	5.8	6.0	6.3	7.0	6.0	6.6	-0.4 (-1.1; 0.3)	2004-2021
Wallonia	N	141	121	125	156	145	142	162	167	151	149	144	151	148	155	115	152	147	160		
	CR	8.1	6.9	7.1	8.8	8.2	7.9	9.0	9.2	8.3	8.1	7.9	8.2	8.0	8.4	6.2	8.2	7.9	8.6		
	ESR2013	8.0	6.8	7.0	8.4	7.7	7.6	8.7	8.6	7.7	7.6	7.2	7.4	7.3	7.7	5.4	7.4	7.2	7.8	-0.5 (-1.5; 0.5)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025